Drug Trial Radar · NCT02531035
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
Last checked: Nov 20, 2026Latest source record: Feb 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,405
Actual
Start
Sep 2015
Primary completion
Apr 2017
Study completion Apr 2017
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
Conditions
- Type 1 Diabetes Mellitus (T1DM)
- High Level of Sugar (Glucose) in the Blood
Interventions
SotagliflozinDrug
Sotagliflozin, once daily, before the first meal of the day
PlaceboDrug
Placebo, once daily, before the first meal of the day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After RandomizationTime frame: Week 24
Locations
135 sites in 19 countries. Site status is shown where the registry gives one.
Lexicon Investigational Site
Concord, California
Lexicon Investigational Site
Escondido, California
Lexicon Investigational Site
La Jolla, California
Lexicon Investigational Site
San Marcos, California
Lexicon Investigational Site
Ventura, California
Lexicon Investigational Site
Walnut Creek, California
Lexicon Investigational Site
Aurora, Colorado
Lexicon Investigational Site
New Haven, Connecticut
Lexicon Investigational Site
Orlando, Florida
Lexicon Investigational Site
West Palm Beach, Florida
Lexicon Investigational Site
Atlanta, Georgia
Lexicon Investigational Site
Macon, Georgia
Lexicon Investigational Site
Roswell, Georgia
Lexicon Investigational Site
New Orleans, Louisiana
Lexicon Investigational Site
Rockville, Maryland
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
Bloomfield Hills, Michigan
Lexicon Investigational Site
Omaha, Nebraska
Lexicon Investigational Site
Las Vegas, Nevada
Lexicon Investigational Site
Albany, New York
Lexicon Investigational Site
The Bronx, New York
Lexicon Investigational Site
Asheville, North Carolina
Lexicon Investigational Site
Chapel Hill, North Carolina
Lexicon Investigational Site
Greenville, North Carolina
Lexicon Investigational Site
Morehead City, North Carolina
Lexicon Investigational Site
Grand Forks, North Dakota
Lexicon Investigational Site
Bend, Oregon
Lexicon Investigational Site
Sioux Falls, South Dakota
Lexicon Investigational Site
Austin, Texas
Lexicon Investigational Site
San Antonio, Texas
Lexicon Investigational Site
Shavano Park, Texas
Lexicon Investigational Site
Salt Lake City, Utah
Lexicon Investigational Site
Seattle, Washington
Lexicon Investigational Site
Buenos Aires, Argentina
Lexicon Investigational Site
Buenos Aires, Argentina
Lexicon Investigational Site
Córdoba, Córdoba Province, Argentina
Lexicon Investigational Site
Coffs Harbour, New South Wales, Australia
Lexicon Investigational Site
Merewether, New South Wales, Australia
Lexicon Investigational Site
St Leonards, New South Wales, Australia
Lexicon Investigational Site
Wollongong, New South Wales, Australia
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.